Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028?
RegulationOne-OffTechHealth & MedicineEquities1yManifold MarketsNo KYCVerified resolution dataFairly calibratedCurrent community forecastYes 70.2%
Forecasters
4
Question type
binary
Methodology
Play-money forecasting platform
Source type
Forecast
Market data
Updated 2 hours ago
StaleAug 6, 26, 4:06 AM UTCDec 31, 27, 11:59 PM UTC
Trends
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will Gustavo Petro face a criminal trial before January 1, 2027?
Manifold MarketsWill the VLA15 Lyme Disease vaccine "pass" its phase 3 human trial?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill Anthropic’s valuation hit __ by September 30?
PolymarketWill OpenAI's valuation hit __ by September 30?
PolymarketAnthropic’s valuation end of October 2026?
PolymarketRules
Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?
- BGE-102 is a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor discovered by BioAge Labs, Inc. (Nasdaq: BIOA).
- NLRP3 drives age-related chronic inflammation implicated in cardiovascular disease, metabolic disorders, and neurodegenerative conditions; BioAge has said its discovery platform nominated NLRP3 from analysis of human aging cohorts in which lower NLRP3 activity tracked with greater longevity (Aug 15, 2025).
- The company has also stated that its compounds engage a binding site and mechanism distinct from other NLRP3 inhibitors in development, with a composition-of-matter patent covering that site issued in January 2026 (Jan 12, 2026).
- Cardiovascular risk reduction is the lead indication.
- This market concerns the QUELL-CV primary endpoint only.
Open markets
RegulationPOLYMARKETClarity Act (H.R.3633) signed into law in 2026?
- No+3.0pt86.1%
- Yes-3.0pt13.9%
- Total Vol
- $14.5M
- 24h Vol
- $253.8K
POLYMARKETAnthropic IPO by which date?
- December 31,-1.0pt90%
- December 15,-1.0pt86%
- November 30,-0.5pt85%
+7 more outcomes
KALSHIWill the Clarity Act become law?
- Before Jul 1, 2027-11.0pt37%
- Before Jan 1, 2028-19.0pt35%
- Before Oct 1, 2027-20.0pt35%
+7 more outcomes
KALSHIWhen will Tesla and SpaceX merge?
- Before 2028+2.0pt67%
- Before May 1, 2027-1.0pt49%
- Before Apr 1, 2027-7.0pt43%
+8 more outcomes
KALSHIWhen will Anthropic officially announce an IPO?
- Before Apr 1, 2027+5.0pt97%
- Before Jan 1, 2027+1.0pt96%
- Before Mar 1, 2027-1.0pt94%
+9 more outcomes
POLYMARKETWhat will OpenAI's IPO valuation be?
- $1.25T–$1.5T-0.1pt19.8%
- $1.75T–$2.0T18.9%
- $1.5T–$1.75T17.9%
+5 more outcomes
- Total Vol
- How many states will adopt data center moratoriums in 2026?
- Conference to Win the National Championship
- Will California authorize an alternative wage or other qualifying relief from goat-herder wage and overtime obligations before Oct 1, 2026?
- Which companies will officially announce an IPO this year?
- Will another state enact a data center moratorium in 2026?
- Discord IPO Closing Market Cap
- When will the Senate vote on the Clarity Act?
- SpaceX' Market Cap end of October 2026?
- Which Senators will vote for the Clarity Act?
- Space Exploration Technologies' Market Cap end of September 2026?
Frequently asked questions
- What are the current odds for Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028??
- Manifold Markets prices Yes at 70% as of September 8, 2026.
- When does Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? resolve?
- Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? is scheduled to resolve on December 31, 2027.
- How is Will BioAge's BGE-102 achieve its primary endpoint in the Phase 2 QUELL-CV trial before January 1, 2028? settled?
- Manifold Markets settles this market as follows: Will BGE-102 significantly reduce hsCRP in BioAge's Phase 2 QUELL-CV trial?